An Observational Study to Determine the Incidence of Injection Reactions Among Patients With Multiple Sclerosis Treated With Ocrelizumab Subcutaneous

Study summary

No information provided.

Study identification

• EU PAS number:
  EUPAS1000001057
• Study ID:
  1000001057
• Official title and acronym:
  An Observational Study to Determine the Incidence of Injection Reactions Among Patients With Multiple Sclerosis Treated With Ocrelizumab Subcutaneous
• DARWIN EU® study:
  No
• Study countries:
  Argentina

  Czechia

  United Kingdom

  United States
• Study description:
  This study will be conducted in patients with multiple sclerosis (MS) in routine clinical care who have newly initiated treatment with ocrelizumab subcutaneous (SC).
• Study status:
  Planned

Research institutions and networks

Institutions

F. Hoffmann-La Roche

Study timelines

Date when funding contract was signed

Planned:30/09/2026

Study start date

Planned:27/01/2027

Data analysis start date

Planned:28/02/2030

Date of final study report

Planned:28/02/2031

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

F. Hoffmann-La Roche Ltd

Regulatory

• Was the study required by a regulatory body?:
  Yes
• Is the study required by a Risk Management Plan (RMP)?:
  EU RMP category 3 (required)

Other study registration identification numbers and links

BN45958